Viviscal for hair loss is one of the most widely recognised over-the-counter hair supplements available in the UK, marketed to reduce shedding and support hair growth in both men and women. Containing a proprietary marine protein complex called AminoMar®, alongside nutrients such as biotin and zinc, it is sold in pharmacies and online without a prescription. As a food supplement regulated under UK food law rather than by the MHRA, it is not subject to the same approval process as licensed medicines. This article examines how Viviscal works, the clinical evidence behind it, who it may help, and how it fits alongside NHS-recognised hair loss treatments.

What Is Viviscal and How Does It Work?

Viviscal is a food supplement containing AminoMar®, a marine protein complex, designed to supply amino acids for keratin synthesis; it is regulated under UK food law, not by the MHRA, and does not act on hormonal pathways.

Viviscal is a food supplement marketed to support hair growth and reduce hair shedding in both men and women. It is available over the counter in the UK without a prescription and is sold in pharmacies, health stores, and online retailers.

As a food supplement, Viviscal is regulated under UK food law, overseen by the Food Standards Agency (FSA) and enforced by Trading Standards, rather than by the Medicines and Healthcare products Regulatory Agency (MHRA). This means it is not subject to the same pre-market approval process required of licensed medicines. Advertising and health claims for food supplements are subject to the Advertising Standards Authority (ASA) and CAP Code rules, and any permitted claims (for example, that biotin and zinc contribute to the maintenance of normal hair) must appear on the GB Nutrition and Health Claims Register.

The primary active ingredient in Viviscal is a proprietary marine protein complex known as AminoMar®, derived from shark and mollusc extracts. The rationale is that amino acids — the building blocks of protein — are essential for the synthesis of keratin, the structural protein that makes up the hair shaft. By supplying these amino acids alongside other nutrients, the supplement aims to nourish hair follicles from within. It is important to note that any effect on the hair cycle is theoretical and has not been independently proven.

In addition to AminoMar®, Viviscal tablets contain a blend of supporting nutrients. The exact composition differs between formulations, and readers should check the current UK product label before use. Ingredients commonly listed include:

• Biotin (Vitamin B7): Contributes to the maintenance of normal hair (permitted EU/GB claim).

• Zinc: Contributes to the maintenance of normal hair and nails.

• Vitamin C: Supports normal collagen formation.

• Iron: Contributes to normal oxygen transport; note that iron may not be present in all formulations (for example, Viviscal Man may differ from Viviscal Extra Strength — always check the label).

• Niacin (Vitamin B3): Supports normal skin function.

Because Viviscal contains marine-derived ingredients, it is not suitable for vegetarians or vegans, and is contraindicated in individuals with fish or shellfish allergies. Viviscal does not act on hormonal pathways in the way that licensed hair loss treatments do.

Not sure if this is normal? Chat with one of our pharmacists →

Types of Hair Loss Viviscal May Help With

Viviscal is most commonly used for androgenetic alopecia and telogen effluvium, but is not appropriate for scarring alopecias, alopecia areata, or hair loss caused by underlying medical conditions.

Hair loss is a broad term encompassing many distinct conditions, and not all types are equally likely to respond to nutritional supplementation. Viviscal is marketed for use in individuals experiencing hair thinning; it is not licensed or indicated to treat any specific medical diagnosis of alopecia.

The two conditions for which it is most commonly used are androgenetic alopecia (pattern hair loss) and telogen effluvium.

Androgenetic alopecia affects both men and women and is driven largely by genetic predisposition and the influence of dihydrotestosterone (DHT) on susceptible hair follicles. In men, this typically presents as a receding hairline or crown thinning; in women, it more commonly causes diffuse thinning across the top of the scalp. Because Viviscal does not inhibit DHT or act on androgen receptors, any potential benefit in androgenetic alopecia is likely limited to nutritional support rather than addressing the underlying hormonal cause.

Telogen effluvium is a temporary, diffuse form of hair shedding often triggered by physiological stressors such as nutritional deficiencies, significant weight loss, illness, surgery, or hormonal changes (including postpartum hair loss). Postpartum telogen effluvium commonly resolves spontaneously within 6–12 months; seek GP review if shedding is persistent or severe. Where shedding is partly driven by inadequate intake of key nutrients — such as iron or zinc — a supplement may offer support by correcting those deficiencies. However, iron supplementation should not be started without blood tests and medical advice, as excess iron can be harmful.

Benefits from nutritional supplementation are most likely when a genuine deficiency has been identified. Biotin deficiency, for example, is rare in people eating a balanced diet, and supplementing biotin in the absence of deficiency is unlikely to produce meaningful hair benefit.

Viviscal is not appropriate for scarring alopecias (such as lichen planopilaris or frontal fibrosing alopecia), alopecia areata (an autoimmune condition), or hair loss caused by underlying medical conditions such as thyroid disease. In these cases, identifying and treating the root cause is essential.

Red flags requiring prompt GP assessment include:

• Sudden or rapid hair loss

• Patchy or asymmetric loss

• Scalp pain, redness, scaling, or inflammation (possible scarring alopecia or tinea capitis)

• Hair loss accompanied by systemic symptoms such as fatigue, weight change, or menstrual irregularity

• Hair loss in children or adolescents

A GP can arrange appropriate investigations (including full blood count, serum ferritin, and thyroid-stimulating hormone; consideration of androgen/PCOS assessment in women with relevant features) and refer to dermatology where indicated.

Evidence and Clinical Research Behind Viviscal

Small manufacturer-funded RCTs show statistically significant increases in terminal hair count and reduced shedding over six months, but sample sizes were limited and no NICE appraisal or Cochrane review exists for Viviscal.

The clinical evidence supporting Viviscal is modest but more extensive than for many competing hair supplements. Several small randomised controlled trials (RCTs) have been published, though the findings should be interpreted with appropriate caution.

A double-blind, placebo-controlled study by Ablon et al., published in the Journal of Clinical and Aesthetic Dermatology (2012), examined women with self-perceived thinning hair. Participants taking Viviscal over six months showed statistically significant increases in the number of terminal hairs and a reduction in hair shedding compared to placebo. A subsequent study in men (Ablon, Journal of Clinical and Aesthetic Dermatology, 2014/2015) reported similar findings, with improvements in hair count and thickness after 180 days of supplementation. Both studies were funded by the manufacturer, which should be taken into account when appraising the results.

Important limitations apply to this evidence base:

• Sample sizes were small (typically 60–120 participants), limiting the generalisability of results.

• Manufacturer funding introduces potential bias in study design, analysis, and reporting.

• Follow-up periods were short (six months), and long-term efficacy and safety data are lacking.

• Studies did not consistently distinguish between participants with nutritional deficiencies and those with adequate baseline nutrient levels, making it difficult to determine who benefits most.

• Absolute effect sizes (for example, changes in terminal hair counts or hair shaft diameter with confidence intervals) were modest and their clinical relevance is uncertain.

There is currently no NICE technology appraisal or Cochrane systematic review specifically evaluating Viviscal. The broader evidence base for nutritional supplementation in hair loss suggests that benefits are most pronounced when a genuine deficiency is present. For individuals with normal nutritional status, the incremental benefit of supplementation remains uncertain.

Clinicians and patients should therefore interpret the available evidence with measured optimism rather than as definitive proof of efficacy, and should not use Viviscal as a substitute for evidence-based medical treatment where one is indicated.

How to Use Viviscal Safely and What to Expect

The standard dose is two tablets daily with food; consistent use for at least three to six months is needed before assessing benefit, and formulations containing iron or zinc should be separated from certain medicines by 2–4 hours.

Viviscal is available in more than one formulation in the UK (including Viviscal Extra Strength and Viviscal Man), each with a slightly different nutrient composition. Always check the current UK product label for the specific ingredients and dosing instructions applicable to the product you are using. The standard recommended dose is two tablets per day, taken with water — typically one in the morning and one in the evening, ideally with food to aid absorption and minimise gastrointestinal discomfort.

Consistency is important. Hair growth is a slow biological process, and most clinical studies have assessed outcomes over a minimum of three to six months. Users should not expect rapid results; it is generally advised to commit to at least three months of regular use before evaluating whether the supplement is having a beneficial effect. Some individuals report noticing reduced shedding within the first few weeks, but visible improvements in hair density typically take longer.

Practical guidance for safe use includes:

• Take at the same time each day to maintain consistent nutrient levels.

• Do not exceed the recommended dose, as higher doses do not confer additional benefit and may increase the risk of adverse effects.

• Store tablets in a cool, dry place away from direct sunlight.

• Keep a photographic record of hair density at baseline and at monthly intervals to objectively assess any changes.

• If the formulation contains iron or zinc, separate the dose by at least 2–4 hours from levothyroxine, bisphosphonates, tetracyclines, and quinolone antibiotics, as these minerals can reduce the absorption of these medicines. Consult your GP or pharmacist if you are unsure.

If any red-flag symptoms develop — such as sudden or rapid hair loss, scalp inflammation, or systemic symptoms (fatigue, weight change) — seek GP advice promptly rather than waiting. If there is no noticeable improvement after six months of consistent use, consult your GP to explore whether an underlying cause requires specific treatment. If you choose to see a trichologist, be aware that trichology is not a statutorily regulated profession in the UK; ensure any practitioner holds appropriate qualifications, and continue to involve your GP in your care.

Side Effects, Allergens, and Who Should Avoid It

Viviscal is contraindicated in fish or shellfish allergy and is unsuitable for vegetarians, vegans, pregnant women, and under-18s; biotin content can interfere with immunoassay blood tests, consistent with MHRA guidance.

Viviscal is generally well tolerated, and serious adverse effects are uncommon. However, there are important safety considerations before starting.

Experiencing these side effects? Our pharmacists can help you navigate them →

Common mild side effects that have been reported include:

• Gastrointestinal discomfort (nausea, bloating, or upset stomach), particularly if taken on an empty stomach.

• Skin reactions in sensitive individuals.

Allergen considerations are particularly important. Viviscal contains marine-derived ingredients (shark powder and mollusc extract), which means it is contraindicated in individuals with fish or shellfish allergies. Allergic reactions, including urticaria, angioedema, or anaphylaxis, are possible in sensitised individuals. Anyone with a known seafood allergy should avoid Viviscal entirely and seek advice from their GP or allergist before considering any marine-based supplement. The product is also not suitable for vegetarians or vegans.

Medicine interactions: If the formulation you are using contains iron or zinc, these minerals can reduce the absorption of levothyroxine, bisphosphonates, tetracyclines, and quinolone antibiotics. Separate doses by at least 2–4 hours. Consult your GP or pharmacist for personalised advice if you take any of these medicines.

Biotin and laboratory tests: Viviscal contains biotin (vitamin B7). Even at relatively low doses, biotin can interfere with certain immunoassay-based blood tests (including thyroid function tests and troponin assays), potentially causing falsely abnormal results. Inform your GP, nurse, or the laboratory if you are taking any biotin-containing supplement before having blood tests. This is consistent with MHRA safety guidance on biotin interference with laboratory immunoassays.

Additional groups who should exercise caution or avoid Viviscal include:

• Pregnant or breastfeeding women: The safety of Viviscal during pregnancy has not been established. Consult your GP or midwife before use.

• Children and adolescents: Viviscal is formulated for adults and is not recommended for those under 18 years of age.

• Individuals taking any new supplement alongside prescribed medicines: Seek advice from your GP or pharmacist before starting.

• Those with haemochromatosis or iron overload conditions: The iron content in certain Viviscal formulations may be inappropriate; check the label and seek medical advice.

• Patients on warfarin or other anticoagulants: As a precaution, seek medical advice before starting any new supplement.

If any unexpected symptoms develop after starting Viviscal, discontinue the supplement and seek advice from a healthcare professional promptly. Suspected adverse reactions to food supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

NHS and NICE Guidance on Hair Loss Treatments in the UK

MHRA-licensed treatments for androgenetic alopecia include topical minoxidil and oral finasteride (men only); Viviscal is not referenced in NICE guidelines and is not available on NHS prescription.

In the UK, the NHS and professional bodies such as the British Association of Dermatologists (BAD) provide guidance on the investigation and management of hair loss. This guidance focuses on licensed medical treatments and evidence-based interventions rather than over-the-counter supplements such as Viviscal.

For androgenetic alopecia, treatments with an established evidence base and UK licensing include:

• Topical minoxidil (available as a solution or foam): Licensed by the MHRA for both male and female pattern hair loss and available over the counter. Refer to the electronic Medicines Compendium (emc) Summary of Product Characteristics (SmPC) for full prescribing information.

• Low-dose oral minoxidil: Not licensed for hair loss in the UK; it is used off-label and is available on private prescription only, requiring clinician oversight and monitoring.

• Finasteride 1 mg (oral, daily): Licensed (MHRA) as a prescription-only medicine (POM) for male pattern baldness in men. It is not recommended for women of childbearing potential due to teratogenic risk. The MHRA has issued Drug Safety Updates highlighting risks of sexual dysfunction (which may persist after stopping), mood changes, and suicidal ideation; a patient alert card is available. Patients should discuss these risks with their prescriber.

• Dutasteride: Used off-label for androgenetic alopecia under specialist supervision; it does not hold a UK licence for this indication.

For alopecia areata, NICE has approved baricitinib (a JAK inhibitor, NICE Technology Appraisal TA885) for severe alopecia areata in adults who meet specific criteria. Topical, intralesional, or systemic corticosteroids may also be used depending on severity, in line with BAD guidance.

The NHS does not routinely fund cosmetic hair loss treatments, and most patients seeking treatment for pattern hair loss will need to access options privately. However, the NHS does investigate and treat hair loss when it is secondary to an underlying medical condition — such as thyroid disease, iron deficiency anaemia, or autoimmune disorders.

When to see your GP: Patients experiencing significant, sudden, or patchy hair loss, or hair loss associated with systemic symptoms, should be assessed by their GP in the first instance. A typical primary care workup includes history and examination, full blood count, serum ferritin, and thyroid-stimulating hormone (TSH); consideration of androgen and PCOS assessment in women with relevant features. Referral to dermatology is appropriate for suspected scarring alopecia, severe or refractory alopecia areata, diagnostic uncertainty, or where specialist treatment is required.

Viviscal is not referenced in NICE guidelines and is not available on NHS prescription. It may serve as a complementary option for individuals seeking nutritional support alongside evidence-based treatments, but it should not be used as a substitute for medical assessment, particularly when hair loss is rapid, patchy, or associated with other symptoms such as fatigue, weight changes, or scalp inflammation. The NHS Hair loss page (nhs.uk) provides authoritative patient-facing information on causes, red flags, and when to seek medical advice.

Frequently Asked Questions